| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Dec, 2028
(4 years from now) | |
| US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(4 years from now) | |
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
| US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US9629841 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
| US10201542 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
Viekira Pak (Copackaged) is owned by Abbvie.
Viekira Pak (Copackaged) contains Dasabuvir Sodium; Ombitasvir, Paritaprevir, Ritonavir.
Viekira Pak (Copackaged) has a total of 21 drug patents out of which 4 drug patents have expired.
Expired drug patents of Viekira Pak (Copackaged) are:
- US6037157
- US6703403
- US7148359
- US7364752
Viekira Pak (Copackaged) was authorised for market use on 19 December, 2014.
Viekira Pak (Copackaged) is available in tablet;oral dosage forms.
Viekira Pak (Copackaged) can be used as treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin., treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin, use of dasabuvir to inhibit viral replication for the treatment of hcv infection., use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection, treatment of hcv infection using ombitasvir, treatment of hcv infection using paritaprevir, treatment of hcv infection using dasabuvir.
Drug patent challenges can be filed against Viekira Pak (Copackaged) from 19 December, 2018.
The generics of Viekira Pak (Copackaged) are possible to be released after 18 October, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Dosing Schedule(D-163) | Apr 22, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection; Treatment of hcv infection using dasabuvir;...
Dosage: TABLET;ORAL
VIEKIRA PAK (COPACKAGED) family patents
